Diabetic Macular Edema - Pipeline Review, H2 2015

Published: October 2015
No. of Pages: 199
   

Global Markets Direct’s, ‘Diabetic Macular Edema Pipeline Review, H2 2015’, provides an overview of the Diabetic Macular Edema’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Diabetic Macular Edema, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Macular Edema and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope


  • The report provides a snapshot of the global therapeutic landscape of Diabetic Macular Edema
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Diabetic Macular Edema and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Diabetic Macular Edema products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Diabetic Macular Edema pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy


  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Diabetic Macular Edema
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Diabetic Macular Edema pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Diabetic Macular Edema - Pipeline Review, H2 2015

Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Diabetic Macular Edema Overview 8
Therapeutics Development 9
Pipeline Products for Diabetic Macular Edema - Overview 9
Pipeline Products for Diabetic Macular Edema - Comparative Analysis 10
Diabetic Macular Edema - Therapeutics under Development by Companies 11
Diabetic Macular Edema - Therapeutics under Investigation by Universities/Institutes 13
Diabetic Macular Edema - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Unknown Stage Products 17
Diabetic Macular Edema - Products under Development by Companies 18
Diabetic Macular Edema - Products under Investigation by Universities/Institutes 21
Diabetic Macular Edema - Companies Involved in Therapeutics Development 22
Aciont Inc. 22
ActiveSite Pharmaceuticals, Inc. 23
Acucela Inc. 24
Aerpio Therapeutics, Inc. 25
Allergan Plc 26
Ampio Pharmaceuticals, Inc. 27
Astellas Pharma Inc. 28
Avalanche Biotechnologies, Inc. 29
Chengdu Kanghong Pharmaceuticals Group Co., Ltd. 30
Chong Kun Dang Pharmaceutical Corp. 31
Dyax Corp. 32
EyeGate Pharmaceuticals, Inc. 33
EyeGene, Inc. 34
F. Hoffmann-La Roche Ltd. 35
Gene Signal International SA 36
Genmab A/S 37
Icon Bioscience, Inc. 38
Kala Pharmaceuticals, Inc. 39
Kowa Company, Ltd. 40
Mabion SA 41
MacuCLEAR, Inc. 42
NicOx S.A. 43
Oculis ehf 44
Ohr Pharmaceutical Inc. 45
Pfizer Inc. 46
Quark Pharmaceuticals, Inc. 47
R-Tech Ueno, Ltd. 48
Regeneron Pharmaceuticals, Inc. 49
Santen Pharmaceutical Co., Ltd. 50
SciFluor Life Sciences, LLC 51
Senju Pharmaceutical Co., Ltd. 52
ThromboGenics NV 53
Verseon Corporation 54
Diabetic Macular Edema - Therapeutics Assessment 55
Assessment by Monotherapy Products 55
Assessment by Combination Products 56
Assessment by Target 57
Assessment by Mechanism of Action 60
Assessment by Route of Administration 62
Assessment by Molecule Type 64
Drug Profiles 66
(aflibercept + nesvacumab) - Drug Profile 66
abicipar pegol - Drug Profile 67
aganirsen - Drug Profile 70
AKB-9778 - Drug Profile 72
ALG-1001 - Drug Profile 74
Antibodies to Inhibit Hemopexin for Diabetic Macular Edema - Drug Profile 76
ASP-440 - Drug Profile 77
ASP-8232 - Drug Profile 79
AVA-101 - Drug Profile 80
conbercept - Drug Profile 82
danazol - Drug Profile 84
dexamethasone acetate - Drug Profile 85
dexamethasone acetate - Drug Profile 87
dexamethasone dipropionate - Drug Profile 89
difluprednate - Drug Profile 90
Drug for Diabetic Macular Edema - Drug Profile 91
Drugs to Inhibit Semaphorin 3A for Diabetic Macular Edema - Drug Profile 92
Drugs to Inhibit Tyrosine Kinase for Ophthalmology - Drug Profile 93
EG-Mirotin - Drug Profile 94
emixustat hydrochloride - Drug Profile 96
KVD-001 - Drug Profile 98
lanadelumab - Drug Profile 99
LKA-651 - Drug Profile 100
loteprednol etabonate - Drug Profile 101
MC-4001 - Drug Profile 102
methotrexate - Drug Profile 103
MTP-131 - Drug Profile 104
NCX-422 - Drug Profile 106
NCX-434 - Drug Profile 107
nesvacumab - Drug Profile 108
NM-108 - Drug Profile 110
ocriplasmin (recombinant) - Drug Profile 111
OLX-303 - Drug Profile 114
PF-04634817 - Drug Profile 115
PF-655 - Drug Profile 116
ranibizumab - Drug Profile 118
ranibizumab biosimilar - Drug Profile 121
ranibizumab biosimilar - Drug Profile 122
RC-1 Alpha - Drug Profile 123
ripasudil - Drug Profile 124
RTU-1096 - Drug Profile 125
RX-10045 - Drug Profile 126
SF-0166 - Drug Profile 128
Small Molecule for Diabetic Macular Edema - Drug Profile 129
Small Molecule to Inhibit Kallikrein for DME - Drug Profile 130
Small Molecules to Inhibit Plasma Kallikrein for DME and HAE - Drug Profile 131
Small Molecules to Inhibit VAP-1 for Diabetic Macular Edema - Drug Profile 133
squalamine lactate - Drug Profile 134
teprotumumab - Drug Profile 137
TG-758 - Drug Profile 139
TG-931 - Drug Profile 140
triamcinolone acetonide - Drug Profile 141
Diabetic Macular Edema - Recent Pipeline Updates 142
Diabetic Macular Edema - Dormant Projects 182
Diabetic Macular Edema - Discontinued Products 185
Diabetic Macular Edema - Product Development Milestones 186
Featured News & Press Releases 186
Appendix 194
Methodology 194
Coverage 194
Secondary Research 194
Primary Research 194
Expert Panel Validation 194
Contact Us 194
Disclaimer 195

List of Tables

Number of Products under Development for Diabetic Macular Edema, H2 2015 13
Number of Products under Development for Diabetic Macular Edema - Comparative Analysis, H2 2015 14
Number of Products under Development by Companies, H2 2015 15
Number of Products under Investigation by Universities/Institutes, H2 2015 17
Comparative Analysis by Late Stage Development, H2 2015 18
Comparative Analysis by Clinical Stage Development, H2 2015 19
Comparative Analysis by Early Stage Development, H2 2015 20
Comparative Analysis by Unknown Stage Development, H2 2015 21
Products under Development by Companies, H2 2015 22
Products under Development by Companies, H2 2015 (Contd..1) 23
Products under Development by Companies, H2 2015 (Contd..2) 24
Products under Investigation by Universities/Institutes, H2 2015 25
Diabetic Macular Edema - Pipeline by Aciont Inc., H2 2015 26
Diabetic Macular Edema - Pipeline by ActiveSite Pharmaceuticals, Inc., H2 2015 27
Diabetic Macular Edema - Pipeline by Acucela Inc., H2 2015 28
Diabetic Macular Edema - Pipeline by Aerpio Therapeutics, Inc., H2 2015 29
Diabetic Macular Edema - Pipeline by Allergan Plc, H2 2015 30
Diabetic Macular Edema - Pipeline by Ampio Pharmaceuticals, Inc., H2 2015 31
Diabetic Macular Edema - Pipeline by Astellas Pharma Inc., H2 2015 32
Diabetic Macular Edema - Pipeline by Avalanche Biotechnologies, Inc., H2 2015 33
Diabetic Macular Edema - Pipeline by Chengdu Kanghong Pharmaceuticals Group Co., Ltd., H2 2015 34
Diabetic Macular Edema - Pipeline by Chong Kun Dang Pharmaceutical Corp., H2 2015 35
Diabetic Macular Edema - Pipeline by Dyax Corp., H2 2015 36
Diabetic Macular Edema - Pipeline by EyeGate Pharmaceuticals, Inc., H2 2015 37
Diabetic Macular Edema - Pipeline by EyeGene, Inc., H2 2015 38
Diabetic Macular Edema - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015 39
Diabetic Macular Edema - Pipeline by Gene Signal International SA, H2 2015 40
Diabetic Macular Edema - Pipeline by Genmab A/S, H2 2015 41
Diabetic Macular Edema - Pipeline by Icon Bioscience, Inc., H2 2015 42
Diabetic Macular Edema - Pipeline by Kala Pharmaceuticals, Inc., H2 2015 43
Diabetic Macular Edema - Pipeline by Kowa Company, Ltd., H2 2015 44
Diabetic Macular Edema - Pipeline by Mabion SA, H2 2015 45
Diabetic Macular Edema - Pipeline by MacuCLEAR, Inc., H2 2015 46
Diabetic Macular Edema - Pipeline by NicOx S.A., H2 2015 47
Diabetic Macular Edema - Pipeline by Oculis ehf, H2 2015 48
Diabetic Macular Edema - Pipeline by Ohr Pharmaceutical Inc., H2 2015 49
Diabetic Macular Edema - Pipeline by Pfizer Inc., H2 2015 50
Diabetic Macular Edema - Pipeline by Quark Pharmaceuticals, Inc., H2 2015 51
Diabetic Macular Edema - Pipeline by R-Tech Ueno, Ltd., H2 2015 52
Diabetic Macular Edema - Pipeline by Regeneron Pharmaceuticals, Inc., H2 2015 53
Diabetic Macular Edema - Pipeline by Santen Pharmaceutical Co., Ltd., H2 2015 54
Diabetic Macular Edema - Pipeline by SciFluor Life Sciences, LLC, H2 2015 55
Diabetic Macular Edema - Pipeline by Senju Pharmaceutical Co., Ltd., H2 2015 56
Diabetic Macular Edema - Pipeline by ThromboGenics NV, H2 2015 57
Diabetic Macular Edema - Pipeline by Verseon Corporation, H2 2015 58
Assessment by Monotherapy Products, H2 2015 59
Assessment by Combination Products, H2 2015 60
Number of Products by Stage and Target, H2 2015 62
Number of Products by Stage and Mechanism of Action, H2 2015 65
Number of Products by Stage and Route of Administration, H2 2015 67
Number of Products by Stage and Molecule Type, H2 2015 69
Diabetic Macular Edema Therapeutics - Recent Pipeline Updates, H2 2015 146
Diabetic Macular Edema - Dormant Projects, H2 2015 186
Diabetic Macular Edema - Dormant Projects (Contd..1), H2 2015 187
Diabetic Macular Edema - Dormant Projects (Contd..2), H2 2015 188
Diabetic Macular Edema - Discontinued Products, H2 2015 189

List of Figures

Number of Products under Development for Diabetic Macular Edema, H2 2015 13
Number of Products under Development for Diabetic Macular Edema - Comparative Analysis, H2 2015 14
Number of Products under Development by Companies, H2 2015 15
Number of Products under Investigation by Universities/Institutes, H2 2015 17
Comparative Analysis by Clinical Stage Development, H2 2015 19
Comparative Analysis by Early Stage Products, H2 2015 20
Assessment by Monotherapy Products, H2 2015 59
Number of Products by Top 10 Targets, H2 2015 61
Number of Products by Stage and Top 10 Targets, H2 2015 61
Number of Products by Top 10 Mechanism of Actions, H2 2015 64
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 64
Number of Products by Top 10 Routes of Administration, H2 2015 66
Number of Products by Stage and Top 10 Routes of Administration, H2 2015 66
Number of Products by Top 10 Molecule Types, H2 2015 68
Number of Products by Stage and Top 10 Molecule Types, H2 2015 68

Published By: Global Markets Direct
Product Code: Global Markets Direct13299


Did you find what you are/were looking for ? If not, read below and browse through other relevant pages for similar market research reports OR get in touch with us through the form/contact info in your right navigation panel and we�ll share relevant market report titles for you to explore.

Related Reports:


Why ReportsnReports.com?

  • 500,000 market research reports and growing.
  • Top Fortune 500 Organizations trust us for research data.
  • 24/7 support on call as well as emails.
  • Your Details are safe with us.
  • Free support for your research requirements.
  • Report Delivery: Email
  • Delivery Time:
    • Upto 24 hrs - working days
    • Upto 48 hrs max - weekends and public holidays

Research Support / Custom Research

If this business study does not have the data and information analysis you need, contact us with your research requirements. We explore available market research reports to map your needs and share report titles with you. Alternatively, we can also offer custom research that suits your budget and timelines. Share your information requirements here.
Connect With Us
Email: sales@reportsandreports.com Call : + 1 888 391 5441

Subscription Option

Using our subscription option, you get access to market research reports and industry data of Pharmaceuticals market as per your needs. Get the best of Pharmaceuticals research reports by utilizing your research budgets in an optimum way.

More about our Subscription option
Email Alerts

Get Email alerts about market research reports from industries and publishers of your interest: